| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447003 | European Journal of Cancer | 2011 | 5 Pages |
Abstract
Treatment for CRC reduces cellular immunity and potentially puts HIV patients at risk of opportunistic infections; knowledge of HIV status prior to starting treatment is essential. This risk may be reduced by concomitant HAART and prophylaxis. Clinicians managing CRC should consider screening patients for HIV before starting chemotherapy or radiotherapy.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Maryam Alfa-Wali, Diana Tait, Tim Allen-Mersh, Paris Tekkis, Mark Nelson, Justin Stebbing, Anthony Antoniou, Mark Bower,